Published in J Urol on September 01, 1999
Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients. J Zhejiang Univ Sci B (2007) 0.84
Genetic alterations in prostate cancer. J Urol (1999) 0.75
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med (1994) 3.20
The cancer genome anatomy project: building an annotated gene index. Trends Genet (2000) 3.02
Experimental Lyme arthritis in rats infected with Borrelia burgdorferi. J Infect Dis (1988) 3.02
Accuracy of frozen-section diagnosis of mammographically directed breast biopsies. Results of 1,490 consecutive cases. Am J Surg Pathol (1995) 3.02
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol (1997) 2.98
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics (1997) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet (1998) 2.60
Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol (1999) 2.59
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A (2001) 2.57
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol (1997) 2.33
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer (2000) 2.28
Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum (1988) 2.21
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 2.19
The histopathology of experimentally infected hamsters with the Lyme disease spirochete, Borrelia burgdorferi. Proc Soc Exp Biol Med (1986) 2.18
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol (1998) 2.14
Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet (1997) 2.09
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann Intern Med (1985) 2.04
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol (1996) 2.04
Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol (1985) 2.03
Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate (1999) 2.02
Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol (1986) 2.01
Inflammatory pseudotumor and sarcoma of urinary bladder: differential diagnosis and outcome in thirty-eight spindle cell neoplasms. Mod Pathol (2001) 1.92
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet (1997) 1.90
Hereditary papillary renal cell carcinoma. J Urol (1994) 1.87
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester. Mayo Clin Proc (1995) 1.84
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
Prevalence of Borrelia burgdorferi in white-footed mice and Ixodes dammini at Fort McCoy, Wis. J Clin Microbiol (1987) 1.82
A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res (1997) 1.82
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab (2000) 1.80
Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (1987) 1.79
Patterns of progression in prostate cancer. Lancet (1986) 1.78
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Experimental infection of the hamster with Borrelia burgdorferi. Ann N Y Acad Sci (1988) 1.77
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet (1997) 1.77
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol (1994) 1.73
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet (1997) 1.70
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med (1999) 1.65
The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA (1996) 1.65
Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med (1993) 1.65
Evaluation of the initial care of hypertensive patients. JAMA (1971) 1.64
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol (1996) 1.64
Prostatic adenocarcinoma with glomeruloid features. Hum Pathol (1998) 1.63
Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology (1997) 1.63
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
Expression of early growth response genes in human prostate cancer. Cancer Res (1998) 1.62
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62